Shin Nippon Biomedical Laboratories, Ltd. (TYO:2395)

TYO:2395 Ratios and Metrics

Market cap in millions JPY. Fiscal year is April - March.

Total Valuation

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Oct 22, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Market Capitalization	61,282	58,867	59,575	63,197	114,488	70,608
Market Cap Growth	-7.54%	-1.19%	-5.73%	-44.80%	62.15%	142.63%
Enterprise Value	85,066	85,331	83,708	76,950	122,470	74,176
Last Close Price	1472.00	1392.93	1364.82	1396.00	2453.96	1485.73

Price Ratios

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Oct 22, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
PE Ratio	11.41	12.89	12.10	11.43	18.89	9.91
Forward PE	15.21	12.72	11.02	12.72	17.36	13.68
PS Ratio	1.81	1.81	1.84	2.39	4.56	3.98
PB Ratio	1.45	1.35	1.49	1.85	4.34	3.58
P/TBV Ratio	1.55	1.44	1.57	1.98	4.67	3.65
P/FCF Ratio	19.43	18.66	-	-	-	16.01
P/OCF Ratio	7.36	7.07	8.47	30.01	28.59	11.86
PEG Ratio	8.45	0.75	1.13	1.20	0.91	-

EV Ratios

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Oct 22, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
EV/Sales Ratio	2.51	2.62	2.58	2.91	4.88	4.18
EV/EBITDA Ratio	8.47	14.03	14.96	12.76	17.89	13.81
EV/EBIT Ratio	13.29	32.16	28.04	18.49	23.35	17.68
EV/FCF Ratio	26.97	27.06	-	-	-	16.82

Financial Efficiency

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Oct 22, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Debt / Equity Ratio	0.89	0.95	0.86	0.77	0.71	0.46
Debt / EBITDA Ratio	5.25	6.78	6.16	4.34	2.74	1.70
Debt / FCF Ratio	-	13.08	-	-	-	2.07
Net Debt / Equity Ratio	0.55	0.52	0.56	0.46	0.31	0.11
Net Debt / EBITDA Ratio	3.25	3.74	4.01	2.58	1.20	0.40
Net Debt / FCF Ratio	-	7.20	-5.88	-2.40	-9.86	0.49
Asset Turnover	0.36	0.33	0.38	0.40	0.52	0.47
Inventory Turnover	1.27	1.18	1.24	1.24	2.06	1.91
Quick Ratio	0.54	0.65	0.63	0.69	0.73	0.79
Current Ratio	1.02	1.09	1.13	1.31	1.14	1.21
Return on Equity (ROE)	13.66%	10.85%	13.10%	18.24%	26.26%	40.30%
Return on Assets (ROA)	2.32%	1.68%	2.21%	3.90%	6.79%	6.88%
Return on Invested Capital (ROIC)	3.89%	2.99%	4.30%	7.81%	14.49%	17.05%
Return on Capital Employed (ROCE)	5.80%	4.00%	4.70%	7.90%	14.50%	16.20%

Yields

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Oct 22, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Earnings Yield	8.76%	7.76%	8.27%	8.75%	5.29%	10.09%
FCF Yield	5.15%	5.36%	-6.41%	-10.25%	-0.73%	6.25%
Dividend Yield	3.40%	3.54%	3.49%	3.29%	1.82%	1.77%
Payout Ratio	38.76%	45.62%	42.65%	37.48%	41.01%	11.60%
Buyback Yield / Dilution	-	-	-	-	0.00%	-
Total Shareholder Return	3.40%	3.54%	3.49%	3.29%	1.82%	1.77%

Data Source: S&P Global Market Intelligence Last updated: Aug 5, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 22, 2026

Data Sources Report a data error